A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis

INTRODUCTION: When making treatment decisions, oncologists often stratify breast cancer (BC) into a low-risk group (low-grade estrogen receptor-positive (ER+)), an intermediate-risk group (high-grade ER+) and a high-risk group that includes Her2+ and triple-negative (TN) tumors (ER-/PR-/Her2-). None...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Dong-Yu, Done, Susan J, McCready, David R, Boerner, Scott, Kulkarni, Supriya, Leong, Wey Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262204/
https://www.ncbi.nlm.nih.gov/pubmed/21939527
http://dx.doi.org/10.1186/bcr3017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262204/
https://www.ncbi.nlm.nih.gov/pubmed/21939527
http://dx.doi.org/10.1186/bcr3017

Ejemplares similares